Coeptis Therapeutics Holdings, Inc.

NasdaqCM:COEP Stock Report

Market Cap: US$102.1m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Coeptis Therapeutics Holdings Management

Management criteria checks 3/4

Coeptis Therapeutics Holdings' CEO is Dave Mehalick, appointed in Oct 2016, has a tenure of 9.5 years. total yearly compensation is $597.00K, comprised of 60.3% salary and 39.7% bonuses, including company stock and options. directly owns 5.31% of the company’s shares, worth $5.42M. The average tenure of the management team and the board of directors is 9.3 years and 3.9 years respectively.

Key information

Dave Mehalick

Chief executive officer

US$597.0k

Total compensation

CEO salary percentage60.30%
CEO tenure9.5yrs
CEO ownership5.3%
Management average tenure9.3yrs
Board average tenure3.9yrs

Recent management updates

Recent updates

Analysis Article • Jun 18

Coeptis Therapeutics Holdings (NASDAQ:COEP) Has Debt But No Earnings; Should You Worry?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

CEO Compensation Analysis

How has Dave Mehalick's remuneration changed compared to Coeptis Therapeutics Holdings's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025US$597kUS$360k

-US$12m

Sep 30 2025n/an/a

-US$12m

Jun 30 2025n/an/a

-US$11m

Mar 31 2025n/an/a

-US$10m

Dec 31 2024US$360kUS$360k

-US$11m

Sep 30 2024n/an/a

-US$12m

Jun 30 2024n/an/a

-US$16m

Mar 31 2024n/an/a

-US$16m

Dec 31 2023US$360kUS$360k

-US$21m

Sep 30 2023n/an/a

-US$20m

Jun 30 2023n/an/a

-US$20m

Mar 31 2023n/an/a

-US$26m

Dec 31 2022US$362kUS$287k

-US$38m

Sep 30 2022n/an/a

-US$37m

Jun 30 2022n/an/a

-US$38m

Mar 31 2022n/an/a

-US$31m

Dec 31 2021US$217kUS$217k

-US$13m

Sep 30 2021n/an/a

-US$15m

Jun 30 2021n/an/a

-US$11m

Mar 31 2021n/an/a

-US$9m

Dec 31 2020US$149kUS$149k

-US$9m

Dec 31 2019US$147kUS$147k

-US$2m

Compensation vs Market: Dave's total compensation ($USD597.00K) is about average for companies of similar size in the US market ($USD616.50K).

Compensation vs Earnings: Dave's compensation has increased whilst the company is unprofitable.

CEO

Dave Mehalick (56 yo)

9.5yrs
Tenure
US$597,000
Compensation

Mr. David Mehalick, also known as Dave, is Chief Business Officer at Sparta Healthcare Acquisition Corp. He is a co-founder of Coeptis Therapeutics Holdings, Inc. (formerly known as Coeptis Therapeutics, I...

Leadership Team

NamePositionTenureCompensationOwnership
David Mehalick
Co-Founder9.5yrsUS$597.00k5.31%
$ 5.4m
Christine Sheehy
Co-Founder9.3yrsUS$75.00k1.03%
$ 1.1m
Daniel Yerace
Co-Founderno dataUS$452.00k1.13%
$ 1.2m
Brian Cogley
Chief Financial Officer2.9yrsUS$310.39k0.36%
$ 369.0k
9.3yrs
Average Tenure
49yo
Average Age

Experienced Management: COEP's management team is seasoned and experienced (9.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
David Mehalick
Co-Founder5.2yrsUS$597.00k5.31%
$ 5.4m
Daniel Yerace
Co-Founder5.2yrsUS$452.00k1.13%
$ 1.2m
Philippe Deschamps
Independent Director3.5yrsno data0.14%
$ 146.8k
Christopher Cochran
Independent Director3.5yrsno data0.14%
$ 146.8k
Eugene Salkind
Independent Director3.5yrsno data0.21%
$ 215.8k
Christopher Calise
Independent Director9.3yrsno data5.93%
$ 6.0m
Evren Alici
Member of Scientific & Clinical Advisory Board4.3yrsno datano data
Hans-Gustaf Ljunggren
Member of Scientific & Clinical Advisory Board4.3yrsno datano data
Arnika Wagner
Member of Scientific & Clinical Advisory Board4.3yrsno datano data
Tara DeSilva
Independent Director3.5yrsno data0.14%
$ 146.8k
Bryan Fuerst
Directorless than a yearno datano data
Adam Sohn
Directorless than a yearno datano data
3.9yrs
Average Tenure
56yo
Average Age

Experienced Board: COEP's board of directors are considered experienced (3.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/27 15:00
End of Day Share Price 2026/04/24 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Coeptis Therapeutics Holdings, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael KingD. Boral Capital LLC.
Aydin HuseynovLadenburg Thalmann & Company